Nasus Pharma's NS002 reaches therapeutic epinephrine threshold faster than autoinjector in Phase 2 trial
NSRX•Nasus Pharma said its investigational intranasal epinephrine powder NS002 reached therapeutic levels faster than an autoinjector in a Phase 2 trial. A pivotal study is planned to begin before year-end 2026, with topline results expected in the first quarter of 2027.
1. Phase 2 results
Nasus Pharma presented Phase 2 NP007 results for NS002 at the ACAAI annual meeting, held November 12-16, 2026. The powder reached therapeutic levels faster than an autoinjector with single and repeat dosing, and results suggested potential superiority under severe nasal congestion; no serious adverse events were observed.
2. Next study
The company plans to begin a pivotal study before year-end 2026 and expects topline results in the first quarter of 2027.




